The body's own repair signal
Injection · 503A Compounding
Educational content. This page describes Thymosin Beta-4 for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
Enhanced bone-fracture healing with greater callus vascularity in mice, supporting interest in the peptide for recovery from bone and soft-tissue injury.[10]
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide first isolated from calf thymus tissue more than four decades ago. It is the most abundant member of the beta-thymosin family and is present in nearly all human cells, with especially high concentrations in platelets, neutrophils, macrophages, and wound fluid. Its core housekeeping job is to bind monomeric G-actin and hold a reservoir of unpolymerized actin ready for rapid filament assembly when a cell needs to move or repair itself.
TB-500 is the name used in the research-chemical and wellness market for a synthetic fragment built around the active sequence Ac-LKKTETQ derived from thymosin beta-4. The full peptide and the fragment share the same actin-regulating core. On the FDA's 503A bulk-substances list the molecule is tracked specifically as 'Thymosin Beta-4, Fragment (LKKTETQ)', the TB-500 form. Scientific interest widened sharply after a 2007 Nature paper reported that the peptide could reawaken progenitor cells in the adult heart.
Most of what is known about thymosin beta-4 comes from cell-culture and animal studies. Human data exist but are limited to early-stage trials run by RegeneRx Biopharmaceuticals in cardiac, ophthalmic, and dermal indications, none of which has yet produced an FDA-approved product.
At the molecular level, thymosin beta-4 sequesters G-actin in a 1:1 complex, keeping unpolymerized actin available so cells can quickly rebuild their cytoskeleton during migration. This actin-buffering role, established in living cells in the early 1990s, underpins most of its downstream repair effects.
The peptide promotes cell movement central to healing. Purified thymosin beta-4 stimulates directional migration of human umbilical-vein endothelial cells and accelerates keratinocyte migration and wound closure in animal models, which is why it is studied for skin, corneal, and vascular repair.
It dampens inflammation by inhibiting TNF-alpha-induced NF-kappaB activation through interactions with PINCH-1 and integrin-linked kinase, reducing inflammatory cytokine output. In rodent heart-injury models it also activates dormant epicardial progenitor cells and supports cardiomyocyte survival after ischemia.
The body's own repair signal
Thymosin beta-4 buffers G-actin to keep cells primed for migration and repair, promotes endothelial and keratinocyte movement for wound healing and angiogenesis, inhibits NF-kappaB-mediated inflammation via PINCH-1 and ILK, and in animal hearts reactivates epicardial progenitor cells and protects cardiomyocytes after injury.
Recombinant thymosin beta-4 was safe and well-tolerated across the dose range tested, with only mild-to-moderate adverse events and no dose-limiting toxicities. This is the most direct human safety signal published for the full peptide.
Wang X, Liu L, Qi L, et al. · J Cell Mol Med, 25(17):8222-8228 (2021) · PubMed
Topical thymosin beta-4 produced statistically significant reductions in ocular discomfort and corneal fluorescein staining versus vehicle, the strongest human efficacy data in any indication. The trial was small, so results are preliminary.
Sosne G, Dunn SP, Kim C · Cornea, 34(5):491-6 (2015) · PubMed
Thymosin beta-4 mobilized adult epicardial progenitor cells, induced neovascularization, and supported new vascular cell formation. This animal finding launched the cardiac-regeneration research program.
Smart N, Risebro CA, Melville AAD, et al. · Nature, 445(7124):177-82 (2007) · PubMed
Topical thymosin beta-4 accelerated corneal epithelial healing while reducing inflammatory markers, providing the preclinical rationale for the later ophthalmic trials.
Sosne G, Szliter EA, Barrett R, et al. · Exp Eye Res, 74(2):293-9 (2002) · PubMed
Administration enhanced fracture healing with increased callus vascularity and bone formation, supporting musculoskeletal-recovery interest. Evidence remains preclinical.
Brady RD, Grills BL, Schuijers JA, et al. · J Orthop Res, 32(10):1277-82 (2014) · PubMed
start low, go slow
Subcutaneous Injection
Subcutaneous Injection: There is no FDA-approved dosing for the TB-500 fragment. The figures above reflect protocols described in the wellness setting, not a validated regimen.
No human dosing has been formally established for the TB-500 fragment. Published clinical trials used different forms entirely (intravenous recombinant peptide for safety work and topical eye drops or gel for ophthalmic and dermal studies), so injectable wellness protocols are extrapolated rather than evidence-based.
In community protocols a higher-frequency loading phase over the first few weeks is typically followed by once-weekly maintenance, with users reporting changes in recovery over a 4-to-12-week window. These timelines come from anecdotal use, not controlled trials.
Any dose, frequency, and cycle length should be set and supervised by a licensed provider based on the individual's condition and goals.
In the first-in-human Phase 1 study, intravenous recombinant thymosin beta-4 was well-tolerated with no dose-limiting toxicities, and the topical Phase 2 dry-eye trial reported no significant safety concerns. These studies were small and short, so the human safety record is thin.
Long-term human safety data are essentially absent. Almost all repair, angiogenesis, and dosing claims for the injectable fragment rest on animal and cell-culture work rather than controlled human trials.
Because the peptide promotes angiogenesis and cell migration, there is a theoretical concern that it could support the growth of an existing tumor. This was among the issues the FDA raised in its review of the fragment.
This page is educational and not medical advice. Use should be supervised by a licensed provider.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Thymosin Beta-4 | Recovery & Healing | Injection | 6–12 weeks | The repair peptide best known for reactivating dormant cardiac progenitor cells in animal hearts, with early human trial data in dry eye |
| GHK-Cu | Anti-Aging & Skin Regeneration | Topical, Injection | 8-12 weeks | A naturally occurring copper-carrier peptide that rebuilds the skin matrix and, per gene-expression analysis, shifts expression of about a third of human genes toward repair |
| BPC-157 | Recovery & Healing | Injection, Oral | 4–8 weeks | Unusually stable in gastric acid; broad multi-system healing signal, though evidence is largely preclinical |
| CJC-1295 | Anti-Aging & Recovery | Subcutaneous injection (weekly with DAC, daily without) | 8-12 weeks | The only GHRH analog with a covalent albumin-binding Drug Affinity Complex, extending its half-life to 6-8 days for once-weekly dosing |
| KPV | Anti-Inflammatory & Wound Healing | Injection, Oral, Topical, Nasal | 4 to 8 weeks | One of the smallest anti-inflammatory peptides, blocking NF-kB nuclear import via PepT1-mediated uptake without melanocortin receptor binding, cAMP elevation, or pigmentation |
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in Category 2 as 'Thymosin Beta-4, Fragment (LKKTETQ)', the form commonly marketed as TB-500. FDA flagged angiogenesis mechanism as a potential tumor-growth concern. Not eligible for compounding under the interim policy.
Listed as 'Thymosin Beta-4, Fragment (LKKTETQ)' in 503A Category 2
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into Thymosin Beta-4? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA tripeptide-copper complex that supports skin regeneration and wound healing.
Naturally occurring in plasma; levels decline with age. Widely used in topical and compounded formulations.
A 15-residue peptide derived from gastric juice, used for tissue and gut repair.
Most studied for tendon, ligament, and GI recovery; controlled human data remains limited.
A stabilized GHRH analog designed to extend the half-life of natural growth hormone pulses.
Widely compounded before 2023; currently flagged by FDA for aggregation and immunogenicity concerns.
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering Thymosin Beta-4.